WHO ICTRP trial
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
PACTR202312651823009 · Pan African Clinical Trials Registry (PACTR) · Recruiting
Key facts
| Trial ID | PACTR202312651823009 |
|---|---|
| Public title | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome |
| Scientific title | A Phase 3, Randomized, Double-blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome |
| Primary sponsor | Janssen Cilag International NV |
| Registry | Pan African Clinical Trials Registry (PACTR) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase-3 |
| Countries | South Africa;South Africa;South Africa;South Africa;South Africa;South Africa;South Africa;South Africa;South Africa;South Africa;South Africa |
| Conditions | Cardiology |
| Registration date | Jan 12, 2023 |
| Target size | 16000 |
| Secondary IDs | 70033093ACS3003 |
| Registry page | pactr.samrc.ac.za |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: